Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Time to Count Recovery after Post-Remission Chemotherapy in AML Patients

Gabrielle Paras, Megan Othus, Carole M. Shaw, Katie Russell, Anna B. Halpern, Jacob S. Appelbaum, Paul C. Hendrie, Roland B. Walter, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 6080–6081.

https://doi.org/10.1182/blood-2022-157586

Published: 2022

Journal Articles

Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia

John J. Lim, Megan Othus, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Roland B. Walter, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 132–134.

https://doi.org/10.1182/blood-2022-169801

Published: 2022

Journal Articles

Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse

Noam E. Kopmar, Megan Othus, Olivia Gilbert, Kelda Schonhoff, Carole M. Shaw, Kathryn Russell, Anna B. Halpern, Jacob S. Appelbaum, Roland B. Walter, Paul C. Hendrie, Bart L. Scott, Mary-Elizabeth M. Percival

Blood (2022) 140 (Supplement 1): 3199–3201.

https://doi.org/10.1182/blood-2022-166526

Published: 2022

Journal Articles

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow

Colin D. Godwin, Yi Zhou, Megan Othus, Mallette M. Asmuth, Carole M. Shaw, Kelda M. Gardner, Brent L. Wood, Roland B. Walter, Elihu H. Estey

Blood (2021) 137 (4): 569–572.

https://doi.org/10.1182/blood.2020006219

Published: 2021

Journal Articles

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Mallette M. Asmuth, MD, Anna B. Halpern, MD, Megan Othus, PhD, Emily Huebner, MS, Carole M. Shaw, BA, Kelda Gardner, PA-C, Elihu H. Estey, MD, Roland B. Walter, MDPhDMS, Colin D. Godwin, MDMPhil

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142730

Published: 2020

Journal Articles

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Colin D. Godwin, MDMPhil, Yi Zhou, MD PhD, Megan Othus, PhD, Carole M. Shaw, BA, Kelda M. Gardner, PA-C, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2729.

https://doi.org/10.1182/blood-2019-127128

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

Kelda Gardner, PA-C, Megan Othus, PhD, Carole M. Shaw, BA, Pamela S. Becker, MD PhD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Bart L. Scott, MD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 5093.

https://doi.org/10.1182/blood-2019-130965

Published: 2019

Journal Articles

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Kelda Gardner, PA-C, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Anna B. Halpern, MD, Carole M. Shaw, BA, Jacob Appelbaum, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 5094.

https://doi.org/10.1182/blood-2019-131280

Published: 2019

Journal Articles

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Noam E. Kopmar, MD, Megan Othus, PhD, Kelda Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Roland B. Walter, MDPhDMS, Pamela S. Becker, MD PhD, Elihu H. Estey, MD, Mary-Elizabeth M. Percival, MD

Blood (2019) 134 (Supplement_1): 2214.

https://doi.org/10.1182/blood-2019-123315

Published: 2019

Journal Articles

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Sarah Mirahsani, Kelda M. Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Mohamed L. Sorror, MD MSc, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 3824.

https://doi.org/10.1182/blood-2019-130834

Published: 2019

NARROW

Time to Count Recovery after Post-Remission Chemotherapy in AML Patients

Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia

Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Covariates Associated with Receipt of High, Intermediate, or Low Intensity Initial Induction in AML or High Risk MDS

AML Clinical Trial Decision Making: How Often Do Physicians Follow a Consensus-Derived Assignment Scheme?

Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only